MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier.
about
Disruption of arterial perivascular drainage of amyloid-β from the brains of mice expressing the human APOE ε4 alleleStructures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domainOlive-oil-derived oleocanthal enhances β-amyloid clearance as a potential neuroprotective mechanism against Alzheimer's disease: in vitro and in vivo studiesEquilibrated atomic models of outward-facing P-glycoprotein and effect of ATP binding on structural dynamics.Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics ConsortiumPreparation of fluorescently-labeled amyloid-beta peptide assemblies: the effect of fluorophore conjugation on structure and functionRapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor.Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's diseaseRegulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrierCerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in miceAlzheimer's and ABC transporters--new opportunities for diagnostics and treatment.Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice.Genetic pathway-based hierarchical clustering analysis of older adults with cognitive complaints and amnestic mild cognitive impairment using clinical and neuroimaging phenotypes.Alterations in function and expression of ABC transporters at blood-brain barrier under diabetes and the clinical significances.Beta-Amyloid Downregulates MDR1-P-Glycoprotein (Abcb1) Expression at the Blood-Brain Barrier in Mice.Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease.The influence of tumour necrosis factor- α (TNF-α) on amyloid-β (Aβ)-degrading enzymes in vitro.Disruption in the Blood-Brain Barrier: The Missing Link between Brain and Body Inflammation in Bipolar Disorder?A-Subclass ATP-Binding Cassette Proteins in Brain Lipid Homeostasis and Neurodegeneration.ABCB1 genotype and CSF beta-amyloid in Alzheimer diseaseABC Transporters and the Alzheimer's Disease Enigma.Aβ1-42 reduces P-glycoprotein in the blood-brain barrier through RAGE-NF-κB signaling.Extra-virgin olive oil attenuates amyloid-β and tau pathologies in the brains of TgSwDI mice.Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders.Role of ABC transporters in the pathogenesis of Alzheimer's diseaseAβ40 Reduces P-Glycoprotein at the Blood-Brain Barrier through the Ubiquitin-Proteasome Pathway.Exploring the contribution of estrogen to amyloid-Beta regulation: a novel multifactorial computational modeling approach.Blood-brain barrier transport of amyloid beta peptides in efflux pump knock-out animals evaluated by in vivo optical imaging.P-glycoprotein transporter in drug development.Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA.The multidrug resistance pump ABCB1 is a substrate for the ubiquitin ligase NEDD4-1Role of ATP-binding cassette transporters in brain lipid transport and neurological disease.Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy.Preparing synthetic Aβ in different aggregation states.Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease.Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease.Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's diseaseAlzheimer's disease and blood-brain barrier function-Why have anti-beta-amyloid therapies failed to prevent dementia progression?Pharmacotherapeutic targets in Alzheimer's diseaseThe blood-brain barrier in neurodegenerative disease: a rhetorical perspective.
P2860
Q27331411-CCDFBF30-2FCC-442C-88ED-00AA2E6F5C16Q27679289-0D4962C0-B94B-4365-90FD-D059C87CF5FBQ28285617-40A7E661-F4B7-4FB7-A290-8A47D950D555Q30636997-5C6245DD-D709-4277-A944-2B3D22203E17Q31041407-790B5C80-8F8F-4303-9FEF-8C70048B82E6Q33682529-2A37010E-3225-444C-8B53-C04F27AF2707Q33697616-839373A5-9244-42C1-B136-8A6513F91886Q33862071-646D3E21-7DE4-4066-BDA1-1E530A82E6A8Q33900889-44D3D19F-5BFC-4087-8309-D0F7508F6911Q34212267-92EF321C-8828-4246-A7B8-195A9B274B47Q34353553-AFBC7B42-118D-4001-A9E3-33F7B35BCC29Q34380018-E5345BA4-B4EF-4274-B9C4-58385E70B5CBQ34494853-B8D0DD31-DA02-4485-BB14-455B49D0F0F2Q34669279-3C029695-CA52-4DE1-98D1-68A0504E08EFQ35030142-DA0F8295-2B6D-40E1-A37B-766DD487C0DBQ35184647-6E685832-7C67-4D0C-B54E-CDAAD7C23CABQ35625868-FD38A495-AAEB-4CA0-8674-8EE4D9D070ABQ35649716-704F0DBC-5F49-409D-A007-66F33F0DFACCQ35801008-CCDC59FC-97C7-42FF-996A-1E71A0D8CE6CQ35801727-D78DD3CF-BCAE-4482-83D9-4CCAD216601EQ36005085-57FB0195-0651-4A11-9A1B-895B37C81710Q36179624-AD46142E-422E-432D-B000-93AEEE1940FAQ36373229-3B9CEF00-A0C4-4614-AC65-9CEFC1D43960Q36378047-17E4D951-ECF1-46AC-BC11-CA184325B7B2Q36418108-F6698324-0A3E-4A46-8392-F8626F5C3FDBQ36564557-BBC5FC38-3357-45A1-8061-EB3508A1AADDQ36648823-70607F80-4413-4124-8DEE-17AE747D2F4FQ36694561-80BA23C4-06D5-4478-9E23-CD40A0CAF821Q36755799-75693D50-247A-4757-A59B-D360033BDC6FQ36772901-B8B99A66-4A1C-4620-94C4-07F4114F574EQ36835064-92A8B374-BE1C-498D-84F6-BEF9ACD2BB01Q36987318-C36DF33E-6E5B-479C-A558-FA9C9A7E266AQ37080236-8D7F531E-D1C7-4EA6-8E7C-B1E9BA5D1366Q37119634-44C33787-22F2-4211-AA5D-3A976244550DQ37124428-62D5F44B-95FA-4DCA-BF2C-876567B71982Q37216153-0BB94F23-398B-43D1-AC88-2E25E0AE59B4Q37239081-D63741C5-016D-4674-BD57-267F0A14C047Q37253310-710DF38C-ABEE-4823-8BF8-0A9D63BD12ABQ37295067-FC44E677-1929-4FD5-B294-2C3BDA16EA89Q37385549-B2118BB9-3D71-4F62-A677-93AC1E1DFBD2
P2860
MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
MDR1-P-Glycoprotein (ABCB1) Me ...... ce at the blood-brain barrier.
@en
MDR1-P-Glycoprotein
@nl
type
label
MDR1-P-Glycoprotein (ABCB1) Me ...... ce at the blood-brain barrier.
@en
MDR1-P-Glycoprotein
@nl
prefLabel
MDR1-P-Glycoprotein (ABCB1) Me ...... ce at the blood-brain barrier.
@en
MDR1-P-Glycoprotein
@nl
P2093
P2860
P50
P1433
P1476
MDR1-P-Glycoprotein (ABCB1) Me ...... ce at the blood-brain barrier.
@en
P2093
Diana Kuhnke
Gabriele Jedlitschky
Heyo K Kroemer
Igor Mosyagin
Markus Grube
Markus Krohn
Rolf W Warzok
Silke Vogelgesang
P2860
P304
P356
10.1111/J.1750-3639.2007.00075.X
P577
2007-07-04T00:00:00Z